EXEM FOAM Bubbles Up Patent Extension: FDA Formality
Published Date: 6/20/2025
Notice
Summary
The FDA has officially set the review period for EXEM FOAM, a human drug product, so its patent can be extended. This means the company behind EXEM FOAM gets more time to protect their invention and keep competitors at bay. If you’re in the drug business, watch the clock—this extension affects when generics can enter the market and could impact money flows.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
EXEM FOAM Patent Extension Set
The FDA has determined the regulatory review period for EXEM FOAM so the company can seek an extension of the drug's patent. The notice follows an application submitted to the Director of the U.S. Patent and Trademark Office (USPTO) and gives the company more time to protect its invention and keep competitors at bay.
Generic Entry Timing Affected
The FDA's determination affects when generic manufacturers can enter the market for EXEM FOAM and could impact money flows in the drug market. If you are in the drug business, this notice signals a change to the timing of generic competition that businesses should monitor.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in